ECSP13012461A - Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor - Google Patents

Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Info

Publication number
ECSP13012461A
ECSP13012461A ECSP13012461A ECSP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A
Authority
EC
Ecuador
Prior art keywords
detect
tor
activity
quinasa
measure inhibition
Prior art date
Application number
Other languages
English (en)
Inventor
Suichan Xu
Lilly Wong
jian hua Ding
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of ECSP13012461A publication Critical patent/ECSP13012461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Proporcionados en la presente se encuentran métodos para detectar y/o medir la inhibición de la actividad quinasa TOR en un sujeto y usos asociados con la misma.
ECSP13012461 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor ECSP13012461A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36945510P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
ECSP13012461A true ECSP13012461A (es) 2013-03-28

Family

ID=45527332

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012461 ECSP13012461A (es) 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Country Status (22)

Country Link
US (1) US20120028972A1 (es)
EP (1) EP2598885B1 (es)
JP (1) JP2013535684A (es)
KR (1) KR20130136970A (es)
CN (1) CN103119445B (es)
AU (1) AU2011282553B2 (es)
BR (1) BR112013002279A2 (es)
CA (1) CA2807147A1 (es)
CO (1) CO6680668A2 (es)
CR (1) CR20130070A (es)
EC (1) ECSP13012461A (es)
ES (1) ES2591135T3 (es)
MX (1) MX337907B (es)
MY (1) MY170983A (es)
NI (1) NI201300013A (es)
NZ (1) NZ606495A (es)
PH (1) PH12013500240A1 (es)
RU (1) RU2587040C2 (es)
SG (1) SG187659A1 (es)
UA (1) UA111724C2 (es)
WO (1) WO2012016113A1 (es)
ZA (1) ZA201300921B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110312916A1 (en) 2009-02-05 2011-12-22 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
TWI629983B (zh) * 2011-10-19 2018-07-21 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
MX360878B (es) * 2012-03-15 2018-11-21 Signal Pharm Llc Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3il)- 3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona para usarse en el tratamiento de carcinoma de células escamosas de cabeza y cuello.
AU2013203714B2 (en) * 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
NZ630467A (en) 2013-01-16 2017-02-24 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
SG10201708111YA (en) * 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
KR20160002792A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
CA2908954C (en) * 2013-04-17 2021-08-03 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
CA2908353C (en) * 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX393164B (es) 2013-04-17 2025-03-21 Signal Pharm Llc Formulaciones farmacéuticas, proceso, formas sólidas y métodos de uso relacionados con 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-ii)piridin-3-ii)-3,4-dihidropirazino[2,3-b]pirazin-2(1h)-ona.
NZ631082A (en) * 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
MX380689B (es) * 2013-04-17 2025-03-12 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US9623028B2 (en) 2014-07-14 2017-04-18 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135298B2 (en) * 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY OF SENSITIVITY OF A TUMOR AGAINST A MTOR INHIBITOR
GB0509748D0 (en) * 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
MX2009004077A (es) * 2006-10-19 2009-05-05 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
MX2013001293A (es) 2013-04-29
WO2012016113A1 (en) 2012-02-02
RU2587040C2 (ru) 2016-06-10
ES2591135T3 (es) 2016-11-25
UA111724C2 (uk) 2016-06-10
EP2598885B1 (en) 2016-07-20
ZA201300921B (en) 2014-04-30
PH12013500240A1 (en) 2013-04-01
KR20130136970A (ko) 2013-12-13
CN103119445B (zh) 2015-10-21
CR20130070A (es) 2013-05-20
CA2807147A1 (en) 2012-02-02
CN103119445A (zh) 2013-05-22
JP2013535684A (ja) 2013-09-12
AU2011282553A1 (en) 2013-03-14
MX337907B (es) 2016-03-28
BR112013002279A2 (pt) 2018-04-24
AU2011282553B2 (en) 2015-04-02
SG187659A1 (en) 2013-03-28
EP2598885A4 (en) 2014-03-26
US20120028972A1 (en) 2012-02-02
MY170983A (en) 2019-09-23
NZ606495A (en) 2014-08-29
EP2598885A1 (en) 2013-06-05
CO6680668A2 (es) 2013-05-31
NI201300013A (es) 2013-04-19
RU2013108840A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
ECSP13012461A (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
IL264770B (en) Diagnostic assays and kits for detection of folate receptor 1
IL288009A (en) Use of inhibitors of bruton's tyrosine kinase (btk)
CO6801640A2 (es) Ensayos interrogatorios basados en células y usos de los mismos
PL2826161T3 (pl) Łączenie pomiarów jakości kanału w oparciu o sygnały odniesienia sondowania i sygnały odniesienia demodulacji
EP2844637A4 (en) SUBSTITUTED 3-HALOALLYLAMININHIBITORS OF SSAO AND USES THEREOF
IL232611A0 (en) Di-converted benzothianyl-pyrrolotriazines and their use as fgfr kinase inhibitors
BR112015001087A2 (pt) métodos para detectar e medir agregação
IL227952A0 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk activity
PT2836847T (pt) Sonda de ensaio e processos relacionados
HK1213046A1 (zh) 動態bh3分析
IL229357B (en) Using location and force measurements to estimate tissue thickness
BR112015002289A2 (pt) aptâmeros cd133 para a detecção de células tronco cancerosas
DK2659071T6 (da) Falsk skillevæg med tredobbelt tykkelse
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
EP2849752A4 (en) CANCER CELL INHIBITING MEDICINE AND CANCER STEM CELL DETECTION PROBE
ES1072702Y (es) Tapon roscado
DK2739748T3 (da) Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
EP2836610A4 (en) METHOD FOR MEASURING POLYMERASE ACTIVITY, USEFUL FOR SENSITIVE QUANTITATIVE MEASUREMENTS OF ANY POLYMERASE EXTENSION ACTIVITIES AND FOR DETERMINING THE PRESENCE OF LIVABLE CELLS
HRP20181744T1 (hr) Komplet za pronalaženje, praćenje i određivanje gvhd
PL3722808T3 (pl) Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam
BR112014028659A2 (pt) métodos de diagnóstico de câncer, erlotinib, usos de um autoanticorpo, kits e invenção
GB201318729D0 (en) Indicator molecules for use in detecting enzyme cleavage activity
UA33298U (ru) Применение пробы с дозированной физической нагрузкой человека как способа оценки состояния антиоксидантной активности
HK1185411A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity